Accure Therapeutics awarded €1 million from Spanish government to evaluate ACT-03 for post-traumatic epilepsy

Accure Therapeutics (Lead coordinator, Barcelona, Spain), Centro Vasco de Neurociencia Achucarro (UPV/EHU, Bilbao, Spain) and Universidad Pompeu Fabra (UPF, Barcelona, Spain) together have received €1 million, combining grants and loan, from the Spanish Ministry of Science, Innovation and University (“Ministerio de ciencia, innovación y universidades”) for executing preclinical in vitro and in vivo experiments to evaluate the effect of ACT-03 in models of post-traumatic epilepsy*.

The funds are from a competitive call through the 2023 public-private partnership (“Proyectos de colaboración Público-Privada”) state programme to support biotech companies and research centres through different programs within the “Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023”.

Roger Prades, Project Director, explains that “ACT-03 is a first-in-class selective inhibitor of matrix metalloproteinases MMP-9 and MMP-2 that has shown promising results in preclinical models of epilepsy to limit the progression of the disease (occurrence and severity of seizures) and associated comorbidities (cognitive impairment)” and “thanks to support from the Spanish Government, the consortium will be able to address important unmet needs, such as to limit, or even prevent, the development of epilepsy”. He added, “In this project, we aim at investigating potential benefits of ACT-03 on restoring Extra Cellular Matrix (ECM) homeostasis to help controlling neuronal hyperexcitability, neuroinflammation, blood-brain barrier functionality and to prevent epileptic focus formation (synapse remodelling)”.

*Proyecto CPP2022-009779 financiado por MCIN/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR.

sellos